EX-99.1
Pfenex: The First U.S. Forteo Biosim And A Host Of Other Biosims In Pipeline (NYSEMKT:PFNX) | Seeking Alpha
Osteoporosis Treatment Market is Poised To Achieve Continuing Growth From US$ 14.01 Bn To US$ 18.92 Bn 2028 With CAGR of 3.8% | Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED. - Digital Journal
ROVI will market TEVA's osteoporosis treatment for adults Tetridar ® ( teriparatide) in Spain
Biosimilar of Forteo launched in Japan by Mochida
Australian and Indian approval for teriparatide products
Top developments in biosimilars during 2019 - GaBI Journal
Pfenex Pitches Teriparatide Pen Against Lilly's Forteo as Partner Alvogen Files In Europe :: Generics Bulletin
Strides Says Forsteo Biosimilar 'Significant Product', Seeks New Minority Investor In Stelis :: Scrip
Biosimilar Hormones Global Market Report 2022: Featuring Teva Pharma, Gedeon Richter, Intas, Biocon, Mylan, Sanofi, Sandoz, LG Life Sciences Ferring & GC Pharma
Biosimilars Law Bulletin | Rothwell Figg | Biologics and Biosimilars Practice
Pfenex: The First U.S. Forteo Biosim And A Host Of Other Biosims In Pipeline (NYSEMKT:PFNX) | Seeking Alpha
Teva and Alvotech collaborate on biosimilars for US market
Pfenex: The First U.S. Forteo Biosim And A Host Of Other Biosims In Pipeline (NYSEMKT:PFNX) | Seeking Alpha
Are new bone drugs from Amgen and Radius cost-effective? Not even close, ICER says | Fierce Pharma
How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline | Biosimilars Law Bulletin
Biosimilars Law Bulletin | Rothwell Figg | Biologics and Biosimilars Practice
Osteoporosis Treatment Market, By Drugs Type, by Route of Administration, by Distribution Channel, and Region - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026
Biosimilar Market Size, Share, Industry Analysis, & Forecast 2029
Teva Pharmaceuticals Near 20-Year Lows (NYSE:TEVA) | Seeking Alpha
Canada approves three teriparatide biosimilars in 2020
